BiotechTube

OKI-219 + Fulvestrant + Trastuzumab + Tucatinib + Atirmociclib + Ribociclib

Phase 1Recruiting
0 watching 0 views this week💤 Quiet
25
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Advanced Cancer

Conditions

Advanced Cancer, Breast Cancer, Advanced Solid Tumors, PI3K Gene Mutation

Trial Timeline

Feb 26, 2024 → Aug 1, 2027

NCT ID
NCT06239467

About OKI-219 + Fulvestrant + Trastuzumab + Tucatinib + Atirmociclib + Ribociclib

OKI-219 + Fulvestrant + Trastuzumab + Tucatinib + Atirmociclib + Ribociclib is a phase 1 stage product being developed by OnKure Therapeutics for Advanced Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06239467. Target conditions include Advanced Cancer, Breast Cancer, Advanced Solid Tumors.

Hype Score Breakdown

Clinical
10
Activity
5
Company
2
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT06239467Phase 1Recruiting

Competing Products

20 competing products in Advanced Cancer

See all competitors
ProductCompanyStageHype Score
AK-105AkesoPhase 1
32
AFM24 + Atezolizumab 840 MG in 14 ML InjectionAffimedPhase 1/2
33
EXS21546BiotrialPhase 1/2
33
SY-1365 (Part 1) + Carboplatin + Fulvestrant + SY-1365 (Cohort 2) + SY-1365 (Cohort 5) + SY-1365 (Part 2 Single Agent)Syros PharmaceuticalsPhase 1
25
Necitumumab + Gemcitabine + CarboplatinEli LillyPhase 2
52
Pemetrexed + Erlotinib + Pemetrexed + ErlotinibEli LillyPhase 2
52
NBTXR3NanobiotixPhase 1/2
36
pegfilgrastim + LY2523355Eli LillyPhase 1
33
SON-1010Sonnet BioTherapeuticsPhase 1
28
SON-1010Sonnet BioTherapeuticsPhase 1/2
36
BT1718Bicycle TherapeuticsPhase 1/2
33
Zentalis + GemzarZentalis PharmaceuticalsPhase 2
44
IMC-18F1Eli LillyPhase 1
33
Tadalafil + GemcitabineEli LillyPhase 1
33
OKI-179OnKure TherapeuticsPhase 1
25
LY3499446 + Abemaciclib + Cetuximab + Erlotinib + DocetaxelEli LillyPhase 1/2
41
LY3434172Eli LillyPhase 1
33
ACR-2316Acrivon TherapeuticsPhase 1
25
BBP-398LianBioPhase 1
25
LY3200882 + PembrolizumabEli LillyPhase 1/2
41

Other Products from OnKure Therapeutics

REN001Phase 2/3
57
Mavodelpar + PlaceboPhase 2
44
OKI-179 + binimetinibPhase 1/2
33
REN001Phase 1
25
OKI-179Phase 1
25